# Trade Mark Journal No.2025/044 31 October 2025

## WO0000001881171 (42,44)

Office of origin: United States of America

Date of International Registration:13 May 2025
Date of designation in the UK: 13 May 2025

International priority date claimed: 13 November 2024 (United States of America) (98851818)

Class 42
  Scientific research; medical research; proteomics and biomarker discovery services; scientific research and development in the fields of pharmaceuticals, therapeutics, and drug formulation and delivery; scientific research and development in the fields of proteomics and biomarker discovery; consultancy services in the field of pharmaceutical research and development services; consultancy services in the fields of proteomics and biomarker discovery; pharmaceutical research services related to prediction of drug treatment efficacy; medical research services related to prediction of drug treatment efficacy; conducting scientific studies in the fields of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification services; scientific and technological research and consultation services, namely, in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, drug repurposing, patient responder identification, indication finding, and rational drug design; drug discovery services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, and rational drug design through optimal pathway effects in intact cells; consultancy in the field of pharmaceutical research and development services in relation to drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, indication finding, and rational drug design through pathway-based structured-activity relationship (SAR).
Class 44
  Medical services; medical testing for diagnosis or treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing medical information, consultancy and advisory services; individual medical counseling services provided to patients; providing information in the field of precision medicine via a website; providing medical information to medical professionals in the form of reports in the field of precision medicine.

Acrivon Therapeutics, Inc.

Representative: Sara M. Bauer Womble Bond Dickinson (US) LLP, Independence Wharf,, 470 Atlantic Ave, Suite 600, Boston MA 02210, UNITED STATES OF AMERICA